A 2014 Global Fund tender resulted in the establishment of framework agreements with diagnostic manufacturers that aimed to make the market for HIV viral load testing more transparent and competitive. This page summarizes the results of that tender and the Global Fund’s procurement strategy for these products.
The 2013 World Health Organization consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection recommend quantitative viral load testing as the preferred monitoring tool for diagnosing and confirming the failure of antiretroviral therapy.
Qualitative viral load is the recommended approach to early infant diagnosis of HIV. Testing for viral load and early infant diagnosis sometimes uses the same technologies, albeit with different reagents and consumables, which is why it is necessary to consider planning and procurement jointly.
The purchase of viral load and/or early infant diagnosis machines can cost more than US$150,000. Reagents and other consumables needed to produce a test results may vary significantly in price, with a range of US$10-85 per test for the reagents alone.
When equipment has been purchased, analysis by partners demonstrate that high and variable costs associated with the testing technologies, low utilization of machines, frequent test malfunctions, and other challenges significantly limit the impact of these investments. Expanding viral load and early infant diagnosis testing can be complex and requires, in addition to the cost of the products, significant investments in infrastructure such as sample transport networks and people.
The Global Fund’s procurement strategy for viral load and early infant diagnosis focuses on both optimizing existing equipment and investments as well as supporting scale-up. The prime focus of the procurement strategy is to achieve simple, transparent and affordable pricing with optimal contracting models for analyzers and/or reagents for both existing and new investments. The strategy emphasizes maintaining a sustainable, competitive market through:
Our interactive HIV Viral Load and Early Infant Diagnosis Selection and Procurement Information Tool provides guidance and clarity for partners procuring HIV viral load and early infant diagnosis technologies.
The information in the tool is continually updated and covers high-level topics including:
We welcome feedback and can provide additional information. Please contact .
A 2015 tender led to the prequalification of suppliers that provide relevant laboratory technical support services. Our list includes those suppliers.
Additional resources are available below to download and access.